Qualify PSMA PET tumour volume as a validated imaging biomarker
PSMA scans could measure prostate cancer burden and response far better than PSA, but no one has done the standardisation work to make the measurement trustworthy across scanners.
Overview
Total PSMA-positive tumour volume and SUV metrics predict outcome in metastatic prostate cancer and response to radioligand therapy, but acquisition, reconstruction and segmentation vary between centres. A QIBA-style profile (phantom calibration, harmonised reconstruction, validated segmentation software) followed by biomarker qualification for defined contexts of use (prognosis, response assessment) would let PSMA volume be used as an endpoint and selection tool in trials.
Similar pages
not linked directly; found by shared links- TrialPOP-RT
Shares PSMA PET, Prostate cancer.
- InstitutionRadboudumc Centre for Oncology
Shares PSMA PET, Prostate cancer.
- PersonThomas A. Hope
Shares PSMA theranostics roadmap: antigen discovery → PSMA PET → 177Lu-PSMA-617 → earlier lines and alpha, PSMA PET, Prostate cancer.
- TrialInvestigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.
Shares PET/CT, Prostate cancer.
- TrialThis Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.
Shares PET/CT, Prostate cancer.
- InstitutionChinese PLA General Hospital
Shares PET/CT, Prostate cancer.
- Key paperVISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer
Shares PSMA PET → PSMA radioligand therapy, PSMA theranostics roadmap: antigen discovery → PSMA PET → 177Lu-PSMA-617 → earlier lines and alpha, PET/CT, PSMA PET.
- IdeaPSMA-PET-guided metastasis-directed therapy as a curative strategy in oligorecurrent prostate cancer
Shares PSMA theranostics roadmap: antigen discovery → PSMA PET → 177Lu-PSMA-617 → earlier lines and alpha, PSMA PET, Prostate cancer.